75N93020F00001↗
Battelle Memorial Institute received this contract from National Institutes of Health Niaid, National Institutes of Health: $0 obligated so far for health r&d services; health care services; applied research. Its period of performance ended 2023-06-30.
Key facts · data as of Oct 28, 2026
- Recipient
- Battelle Memorial Institute
- Awarding agency
- National Institutes of Health (Department of Health and Human Services)
- Contracting office
- National Institutes of Health Niaid (75N930)
- Obligated to date
- $0
- Potential value
- $6.24M
- Ends
- 2023-06-30
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 28, 2026.
Cite this page: SpendQuery, Award 75N93020F00001, data as of Oct 28, 2026, https://spendquery.com/award?id=CONT_AWD_75N93020F00001_7529_75N93018D00013_7529
Battelle Memorial Institute: all federal awards · Department of Health and Human Services: spending · National Institutes of Health Niaid: what it buys
EVALUATE THE IMMUNOLOGICAL RESPONSES OF HUMAN SAMPLES COLLECTED FROM PHASE I AND PHASE II CLINICAL TRIALS OF SEASONAL AND PANDEMIC INFLUENZA VACCINE WITH AND WITHOUT ADJUVANT. CLINICAL TRIAL SAMPLES SHALL BE EVALUATED USING QUALIFIED, HEMAGGLUTININ I
What it is
- Product or service
- Health R&D Services; Health Care Services; Applied Research (PSC AN12)
- Industry
- Research and Development in Nanotechnology (NAICS 541713)
- Contracting office
- National Institutes of Health Niaid (75N930)
- Competition
- Full and open competition
- Pricing
- Cost plus fixed fee
- How it was bought
- Single-award IDIQ · under 75N93018D00013
- Where the work is
- Franklin, OH · district OH-03
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
2 actions since 2022-10-12. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2022-11-03 | P00003 | Supplemental agreement (work within scope) | $0 | EVALUATE THE IMMUNOLOGICAL RESPONSES OF HUMAN SAMPLES COLLECTED FROM PHASE I AND PHASE II CLINICAL TRIALS OF SEASONAL AND PANDEMIC INFLUENZA VACCINE WITH AND WITHOUT ADJUVANT. CLINICAL TRIAL SAMPLES SHALL BE EVALUATED USING QUALIFIED, HEMAGGLUTININ I |
| 2022-10-12 | P00002 | Supplemental agreement (work within scope) | $0 | EVALUATE THE IMMUNOLOGICAL RESPONSES OF HUMAN SAMPLES COLLECTED FROM PHASE I AND PHASE II CLINICAL TRIALS OF SEASONAL AND PANDEMIC INFLUENZA VACCINE WITH AND WITHOUT ADJUVANT. CLINICAL TRIAL SAMPLES SHALL BE EVALUATED USING QUALIFIED, HEMAGGLUTININ I |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-28). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗